{"id":"W4406818361","doi":"10.1016/s0140-6736(24)02848-4","title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Open label; Colorectal cancer; Microsatellite instability; Oncology; Internal medicine; Metastatic melanoma; Phases of clinical research; Cancer; Randomized controlled trial; Immunotherapy; Clinical trial; Microsatellite; Gene; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001573013,0.0003538621,0.001441769,0.0001593677,0.0002117219,0.0001669009,0.0007730353,0.0001213669,0.000479278],"category_scores_gemma":[0.0002179635,0.0002536544,0.0001577625,0.0008891172,0.0003698501,0.0001763781,0.0002075207,0.0004965821,0.00002320969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008951838,"about_ca_system_score_gemma":0.001101519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004811139,"about_ca_topic_score_gemma":0.003566359,"domain_scores_codex":[0.9972744,0.0004284219,0.0007864856,0.0005514989,0.0003032267,0.0006559804],"domain_scores_gemma":[0.9983321,0.0004376382,0.0002174093,0.0008301511,0.0000978045,0.00008482852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9463237,0.001001586,0.0001070692,0.0001757573,0.0007416015,0.00003741596,0.0007335337,0.000008252884,0.02018874,0.0001214734,0.003521005,0.02703985],"study_design_scores_gemma":[0.9650264,0.001796449,0.0006356846,0.0004774037,0.0004371126,0.0000101933,0.0002731981,0.0004357963,0.007683978,0.0002354192,0.02269904,0.0002892987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9811325,0.005539115,0.00002809929,0.003961099,0.001815859,0.004765747,0.000213476,0.00008561218,0.002458508],"genre_scores_gemma":[0.9928327,0.001851346,0.0003478749,0.001600354,0.0004245146,0.001026114,0.0001219243,0.00004278369,0.001752363],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02675055,"threshold_uncertainty_score":0.9999916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06751625483083432,"score_gpt":0.3841724924556876,"score_spread":0.3166562376248533,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}